<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13421">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398411</url>
  </required_header>
  <id_info>
    <org_study_id>05001</org_study_id>
    <secondary_id>2005-003271-21</secondary_id>
    <nct_id>NCT00398411</nct_id>
  </id_info>
  <brief_title>Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells</brief_title>
  <acronym>MoxiProph</acronym>
  <official_title>Double-blind, Randomized, Mono-center, Placebo-controlled Pilot Study to Investigate the Efficacy and Safety of Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates whether the prophylactic use of moxifloxacin during high-dose
      chemotherapy followed by autologous stem cell transplantation reduces the incidence of
      clinically significant bacteremia.

      Further investigations include time to occurrence of fever, duration of fever, overall
      survival and antibiotic sensitivity of blood isolates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Because fluoroquinolones have broad antimicrobial coverage, bactericidal activity, high
      tissue concentrations, oral bioavailability and adequate tolerability and safety profiles,
      they are ideal candidates as antibacterial prophylaxis in cancer patients. Randomized trials
      investigating the effect of an antibiotic prophylaxis on patients with intermediate
      neutropenia have recently been conducted with levofloxacin. The influence of moxifloxacin on
      the incidence of bacteremia in patients undergoing autologous hematopoetic stem cell
      transplantation has not been investigated. Moxifloxacin may be another promising
      alternative, covering a broader spectrum of gram-positive and anaerobic bacteria than first-
      or secondary generation fluoroquinolones and for instance it is an agent administered only
      once daily, thus optimizing compliance, a crucial issue in prophylaxis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence of Clinically Significant Bacteremia</measure>
    <time_frame>end of treatment (mean duration of treatment was 9.7 days; 10.2 days in moxifloxacin arm, 9.2 days in placebo arm)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Failure was defined as clinically significant bacteraemia occurring in the period of neutropenia and an intervention with a systemic antibacterial becoming necessary.
With this being a discontinuation criteria and the outcome being measured at end of treatment, only one episode is taken into account for each participant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of Isolates and Infections</measure>
    <time_frame>end of treatment (mean duration of treatment was 9.7 days; 10.2 days in moxifloxacin arm, 9.2 days in placebo arm)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Occurrence of Fever &gt;= 38°C</measure>
    <time_frame>end of treatment (mean duration of treatment was 9.7 days; 10.2 days in moxifloxacin arm, 9.2 days in placebo arm)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for Discontinuation of Treatment</measure>
    <time_frame>end of treatment (mean duration of treatment was 9.7 days; 10.2 days in moxifloxacin arm, 9.2 days in placebo arm)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Absolute neutrophil count (ANC) recovered to &gt; 500 /µl on two consecutive days Maximum of 20 days of treatment Occurrence of fever &gt;= 38°C Systemic antibiotic treatment despite patient being afebrile Death Other adverse event (AE) Other reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of Infection</measure>
    <time_frame>follow up visit (at discharge from hospital up to a maximum of 28 days after transplantation)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>follow up visit (at discharge from hospital up to a maximum of 28 days after transplantation)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Hodgkin Disease</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Bacteremia</condition>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>moxifloxacin 400 mg tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>identical appearing placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin</intervention_name>
    <description>400 mg p.o. per day</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <other_name>Avalox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>one tablet per day p.o.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo preparation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High-dose chemotherapy followed by peripheral autologous stem cell transplantation

          -  Underlying disease: Hodgkin Disease, non-Hodgkin-lymphoma, multiple myeloma or solid
             tumor

        Exclusion Criteria:

          -  Allogenic stem cell transplantation

          -  Aplastic anemia

          -  Antibiotic treatment within seven days prior to randomization

          -  Signs and symptoms of current infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver A. Cornely, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universität zu Köln</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum der Universität zu Köln</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Vehreschild JJ, Moritz G, Vehreschild MJ, Arenz D, Mahne M, Bredenfeld H, Chemnitz J, Klein F, Cremer B, Böll B, Kaul I, Wassmer G, Hallek M, Scheid C, Cornely OA. Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial. Int J Antimicrob Agents. 2012 Feb;39(2):130-4. doi: 10.1016/j.ijantimicag.2011.10.009. Epub 2011 Dec 12.</citation>
    <PMID>22169408</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 1, 2015</lastchanged_date>
  <firstreceived_date>November 8, 2006</firstreceived_date>
  <firstreceived_results_date>August 5, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Oliver Cornely, MD</investigator_full_name>
    <investigator_title>Medical Director of the Center of Clinical Trials (ZKS)</investigator_title>
  </responsible_party>
  <keyword>prophylaxis</keyword>
  <keyword>bacteremia</keyword>
  <keyword>moxifloxacin</keyword>
  <keyword>stem cell transplantation</keyword>
  <keyword>Hodgkin disease</keyword>
  <keyword>non-Hodgkin lymphoma</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>solid tumor</keyword>
  <keyword>autologous stem cell transplantation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient in: Oct 10, 2006; Last patient, last visit: Dec 08, 2008</recruitment_details>
      <pre_assignment_details>68 patients were intended for inclusion in the trial. Two patients were excluded due to violation of inclusion/exclusion criteria; both received no study drug and they were excluded from the analysis. The remaining 66 participants were evaluable for response analysis in the intention to treat (ITT) set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Moxifloxacin</title>
          <description>moxifloxacin 400 mg tablets once daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>identical appearing placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Moxifloxacin</title>
          <description>moxifloxacin 400 mg tablets once daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>identical appearing placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
                <measurement group_id="B2" value="32"/>
                <measurement group_id="B3" value="66"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="54" lower_limit="21" upper_limit="68"/>
                <measurement group_id="B2" value="50" lower_limit="23" upper_limit="70"/>
                <measurement group_id="B3" value="51.5" lower_limit="21" upper_limit="70"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="25"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="41"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="172.71" spread="8.7"/>
                <measurement group_id="B2" value="173.72" spread="9.7"/>
                <measurement group_id="B3" value="173.2" spread="9.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="76.41" spread="13.9"/>
                <measurement group_id="B2" value="75.00" spread="16.5"/>
                <measurement group_id="B3" value="75.73" spread="15.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Underlying Disease</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hodgkin's Disease</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>NHL</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Multiple Myeloma</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Solid Tumor</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Status of Underlying Disease</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>primary</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="34"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>primary progressive</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>relapsed</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Clinically Significant Bacteremia</title>
        <description>Failure was defined as clinically significant bacteraemia occurring in the period of neutropenia and an intervention with a systemic antibacterial becoming necessary.
With this being a discontinuation criteria and the outcome being measured at end of treatment, only one episode is taken into account for each participant.</description>
        <time_frame>end of treatment (mean duration of treatment was 9.7 days; 10.2 days in moxifloxacin arm, 9.2 days in placebo arm)</time_frame>
        <safety_issue>No</safety_issue>
        <population>intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>moxifloxacin 400 mg tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical appearing placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence of Clinically Significant Bacteremia</title>
            <description>Failure was defined as clinically significant bacteraemia occurring in the period of neutropenia and an intervention with a systemic antibacterial becoming necessary.
With this being a discontinuation criteria and the outcome being measured at end of treatment, only one episode is taken into account for each participant.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Type of Isolates and Infections</title>
        <time_frame>end of treatment (mean duration of treatment was 9.7 days; 10.2 days in moxifloxacin arm, 9.2 days in placebo arm)</time_frame>
        <safety_issue>No</safety_issue>
        <population>intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>moxifloxacin 400 mg tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical appearing placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Type of Isolates and Infections</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>bacteremia isolate: enterococcus faecalis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>bacteremia isolate: escherichia coli</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>bacteremia isolate: klebsiella pneumoniae</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>bacteremia isolate: pseudomonas aeruginosa</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>bacteremia isolate: staphylococcus aureus</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>bacteremia isolate: staphylococcus epidermidis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>bacteremia isolate: streptococcus species</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>clostridium difficile infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>mucositis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Occurrence of Fever &gt;= 38°C</title>
        <time_frame>end of treatment (mean duration of treatment was 9.7 days; 10.2 days in moxifloxacin arm, 9.2 days in placebo arm)</time_frame>
        <safety_issue>No</safety_issue>
        <population>intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>moxifloxacin 400 mg tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical appearing placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Occurrence of Fever &gt;= 38°C</title>
            <units>days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9.50" spread="4.1"/>
                  <measurement group_id="O2" value="7.69" spread="3.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reason for Discontinuation of Treatment</title>
        <description>Absolute neutrophil count (ANC) recovered to &gt; 500 /µl on two consecutive days Maximum of 20 days of treatment Occurrence of fever &gt;= 38°C Systemic antibiotic treatment despite patient being afebrile Death Other adverse event (AE) Other reason</description>
        <time_frame>end of treatment (mean duration of treatment was 9.7 days; 10.2 days in moxifloxacin arm, 9.2 days in placebo arm)</time_frame>
        <safety_issue>No</safety_issue>
        <population>intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>moxifloxacin 400 mg tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical appearing placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Reason for Discontinuation of Treatment</title>
            <description>Absolute neutrophil count (ANC) recovered to &gt; 500 /µl on two consecutive days Maximum of 20 days of treatment Occurrence of fever &gt;= 38°C Systemic antibiotic treatment despite patient being afebrile Death Other adverse event (AE) Other reason</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>recovery of absolute neutrophil count</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>maximum of 20 days of treatment</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>premature discontinuation: occurence of fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>premature discontinuation: antibiotic treatment</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>premature discontinuation: death</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>premature discontinuation: other adverse event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>premature discontinuation: other reason</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Type of Infection</title>
        <time_frame>follow up visit (at discharge from hospital up to a maximum of 28 days after transplantation)</time_frame>
        <safety_issue>No</safety_issue>
        <population>intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>moxifloxacin 400 mg tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical appearing placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Type of Infection</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>peri-anal abscess</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>mucositis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>pulmonary infiltrate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>infection at venous catheter</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>herpes infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>candida infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>acute respiratory syndrome</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>clostridium difficile infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>atypical pneumonia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>follow up visit (at discharge from hospital up to a maximum of 28 days after transplantation)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>moxifloxacin 400 mg tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical appearing placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Survival</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AE) have been documented throughout study duration, serious adverse events (SAE) until 4 weeks after end of study.</time_frame>
      <desc>The following AE have been documented in the trial but are not reported in this section unless as SAE:
Infections, already reported as outcome measures.
Expected AE as defined in the protocol: leukopenia, anemia, thrombocytopenia, including their manifestations; hepatosplenomegaly, bone pain, increase of lactate dehydrogenase, hyperuricemia.</desc>
      <group_list>
        <group group_id="E1">
          <title>Moxifloxacin</title>
          <description>moxifloxacin 400 mg tablets once daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>identical appearing placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac arrest</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholecystitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>atypical pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>staphyloccocus epidermidis sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>increase of CRP</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="36" subjects_affected="26" subjects_at_risk="34"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>heartburn / reflux</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="52" subjects_affected="31" subjects_at_risk="34"/>
                <counts group_id="E2" events="42" subjects_affected="24" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="32" subjects_affected="24" subjects_at_risk="34"/>
                <counts group_id="E2" events="32" subjects_affected="20" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal cramps</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="37" subjects_affected="26" subjects_at_risk="34"/>
                <counts group_id="E2" events="42" subjects_affected="26" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="34"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="35" subjects_affected="25" subjects_at_risk="34"/>
                <counts group_id="E2" events="28" subjects_affected="22" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>increase of bilirubin</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>increase of liver enzymes</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="20" subjects_affected="10" subjects_at_risk="34"/>
                <counts group_id="E2" events="25" subjects_affected="13" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="35" subjects_affected="27" subjects_at_risk="34"/>
                <counts group_id="E2" events="45" subjects_affected="31" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>cramps in the calf</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>dysuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>increase of creatinine</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>exanthema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Dr. Oliver A. Cornely</name_or_title>
      <organization>University of Cologne</organization>
      <phone>+49 221 478 88794</phone>
      <email>oliver.cornely@zks-koeln.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
